The American Journal of Managed Care

CheckMate 9LA at 6 Years Shows Enduring Benefits From Dual Immunotherapy Plus Chemotherapy in Metastatic NSCLC

CheckMate 9LA showed a 26% overall survival benefit for metastatic NSCLC patients treated with nivolumab and ipilimumab plus ...
pharmaphorum

Hengrui gets first OK for a PD-L1/TGF-beta drug for cancer

Jiangsu Hengrui Pharma has chalked up a first-in-class approval for retlirafusp alfa, a bifunctional drug that targets PD-L1 ...
The American Journal of Managed Care

Higher TMB, PD-L1 Expression Correlate With Shorter Survival in Hematologic Malignancies

A new analysis of real-world data show that just as in solid tumors, higher tumor mutational burden (TMB) and PD-L1 expression in blood cancers are linked to less-optimistic prognoses. Their ...
ascopubs.org

PD-L1 Expression in Biliary Tract Cancer: Comparison Across Antibody Clones and Role as a Predictor of Response to Chemoimmunotherapy: A Meta-Analysis

Factors Associated With Implementation of Biomarker Testing and Strategies to Improve Its Clinical Uptake in Cancer Care: Systematic Review Using Theoretical Domains Framework Observational studies or ...
Antelope Valley Press

Head-to-Head Real-World Data: Cadonilimab Outperforms PD-1 Inhibitors in First-Line PD-L1-Low Gastric Cancer

Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
Business Wire

U.S. FDA and CEL-SCI Agree on Use of PD-L1 Biomarker to Select Head and Neck Cancer Patients for Marketing Registration Study to Commence Q1 2025

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced that in a recent meeting the U.S. Food and Drug Administration (FDA) concurred with the Company’s approach to ...
News Medical

Immuno-PET imaging for assessing PD-L1 expression in glioblastoma tumors

Patients with Glioblastoma (GBM), a highly aggressive malignant brain tumor, have an extremely poor prognosis due to a lack of viable treatment choices. Since being named the “breakthrough of the year ...
Business Wire

FDA’s Oncologic Drugs Advisory Committee Decision on Checkpoint Inhibitors Substantiates Potential of CEL-SCI’s Multikine® to Address Major Treatment Gap for PD-L1 ...

VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the potential positive impact on the clinical development of its immunotherapy Multikine® (Leukocyte Interleukin, ...